Results 181 to 190 of about 131,644 (347)

Prophylactic Management of Vestibular Migraine: A Systematic Review

open access: yesAnnals of Clinical and Translational Neurology, Volume 12, Issue 12, Page 2384-2397, December 2025.
ABSTRACT Background Vestibular migraine (VM) is a neurological disorder characterized by episodic vertigo in patients with migraine, contributing to substantial functional impairment. Although VM is relatively common, a consensus on effective prophylactic treatments is lacking.
Hussain Ali Almohammed   +11 more
wiley   +1 more source

Randomized trial of the effect of esomeprazole on functional dyspepsia during Ramadan fasting. [PDF]

open access: yesSci Rep
Hadrich S   +34 more
europepmc   +1 more source

The Result Discrepancies between Histological and PCR Method for Detecting Helicobacter pylori in Patients with Dyspepsia due to Inappropriate Preparation before Endoscopy

open access: green, 2009
Maruni Wiwin Diarti   +7 more
openalex   +2 more sources

Adverse drug reactions, particularly liver disorders, drive interruptions in anti‐tuberculosis treatment: A retrospective cohort study

open access: yesBritish Journal of Clinical Pharmacology, Volume 91, Issue 12, Page 3461-3470, December 2025.
Aims Adverse drug reactions (ADRs) are a key driver of missed doses of anti‐tuberculosis (TB) therapy. We aimed to determine the relative burden of ADR‐driven missed doses, the missed dose patterns associated with ADRs, and the association between specific ADRs and missed doses.
Eleanor G. Dixon   +10 more
wiley   +1 more source

Electroacupuncture Upregulated Ghrelin in Rats with Functional Dyspepsia via AMPK/TSC2/Rheb-Mediated mTOR Inhibition [PDF]

open access: hybrid, 2019
Lei Tang   +7 more
openalex   +1 more source

A Phase II Pilot Study of Anti‐PD‐L1, Durvalumab, and a PARP Inhibitor, Olaparib in Patients With Metastatic Triple‐Negative Breast Cancer With or Without Germline BRCA Mutation

open access: yesCancer Medicine, Volume 14, Issue 23, December 2025.
ABSTRACT Background Immunostimulatory effects of PARP inhibitors could increase sensitivity to immune checkpoint inhibitors. The previous Phase II trial (MEDIOLA) reported clinical benefits of durvalumab and olaparib (D + O) in patients with germline BRCA‐mutated (gBRCAm) HER2‐negative metastatic breast cancer.
Takeo Fujii   +13 more
wiley   +1 more source

Home - About - Disclaimer - Privacy